Loading
OmicXScreen is an investigational blood test from OmicXHealth that reads DNA patterns to look for early liver cancer, with other cancers in development.
OmicXScreen is the early cancer detection platform of OmicXHealth. The company reports preclinical validation for hepatocellular carcinoma, a lung cancer classifier and proof of concept in six cancer types. The National Cancer Institute funds an SBIR project on the test for early hepatocellular carcinoma and oesophageal cancer detection (1R43CA310377-01A1). It is not cleared or approved by a regulator.
Sequences cell-free DNA from a blood sample once across the whole genome and analyses methylation patterns in software with machine-learning models to detect early cancer.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"OmicXScreen" OR ABSTRACT:"OmicXScreen") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about OmicXScreen, not a curated reading list.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/